{"id":7920,"date":"2026-06-18T15:15:56","date_gmt":"2026-06-18T19:15:56","guid":{"rendered":"https:\/\/cqdm.org\/?post_type=project&p=7920"},"modified":"2026-06-18T15:24:10","modified_gmt":"2026-06-18T19:24:10","slug":"new-method-for-the-purification-and-synthesis-of-therapeutic-oligonucleotides-using-next-generation-chemistry","status":"publish","type":"project","link":"https:\/\/cqdm.org\/en\/achievement\/funded-projects\/new-method-for-the-purification-and-synthesis-of-therapeutic-oligonucleotides-using-next-generation-chemistry\/","title":{"rendered":"New method for the purification and synthesis of therapeutic oligonucleotides using next\u2011generation chemistry"},"content":{"rendered":"\n
\n
<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
\n
\n

Principal Entit<\/strong>y<\/p>\n\n\n\n

Galenvs Sciences Inc.<\/strong>
<\/p>\n<\/div>\n\n\n\n

\n

Co-investigator<\/strong><\/p>\n\n\n\n

Martin Sauvageau
<\/b><\/span>Institut de recherches cliniques de Montr\u00e9al (IRCM)<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n\n\n\n

Project <\/span>of $599,598 over 18 months<\/h2>\n\n\n\n
    \n
  • Supported by CQDM through:<\/strong><\/strong>
    Minist\u00e8re de l\u2019\u00c9conomie, de l\u2019Innovation et de l\u2019\u00c9nergie du Qu\u00e9bec (MEIE)<\/li>\n\n\n\n
  • And by co-funding partner:<\/strong><\/strong><\/strong>
    – Galenvs Sciences Inc.
    – Foundation de l\u2019IRCM
    – IRCM<\/li>\n<\/ul>\n\n\n\n
    \n\n\n\n

    Challenge:<\/h3>\n\n\n\n

    The manufacturing of therapeutic oligonucleotides still relies predominantly on HPLC based purification processes. While effective for analytical purposes, these methods are economically, industrially, and environmentally limiting. They are costly, difficult to scale, and generate substantial volumes of organic solvents and waste. As the RNA therapeutics market expands rapidly\u2014and as next generation chemistries and increasingly complex oligonucleotide architectures become essential for optimizing clinical performance\u2014these constraints represent major bottlenecks for production capacity. Developing integrated, scalable, and sustainable purification and synthesis platforms is therefore critical to support the industrialization and clinical adoption of next generation therapeutic oligonucleotides.<\/p>\n\n\n\n

    Solution:<\/h3>\n\n\n\n

    This project, led by Galenvs Sciences in collaboration with Prof. Martin Sauvageau at the IRCM, will develop high throughput purification and synthesis strategies for therapeutic RNA molecules, including siRNA and ASO. The primary objective is to eliminate reliance on HPLC by implementing approaches compatible with automation and adaptable to modern oligonucleotide manufacturing pipelines. In parallel, the project will focus on adapting conventional solid phase oligonucleotide synthesis protocols to accommodate new nucleic acid chemistries\u2014modifications that are increasingly important in therapeutic applications due to their enhanced stability, reduced immunogenicity, and unique pharmacokinetic properties.<\/p>\n\n\n\n

    Expected Achievements \/Impacts<\/strong>:<\/h3>\n\n\n\n

    By addressing two major bioproduction challenges\u2014large scale purification and compatibility of new chemistries with solid phase synthesis\u2014the project will enable cost effective, high quality production of complex oligonucleotide therapeutics. This will accelerate the development and reduce the cost of next generation RNA therapeutics in Qu\u00e9bec. This strategic investment will help build world class Qu\u00e9bec expertise in the RNA and oligonucleotide sector, an area poised to transform medicine and biotechnology. In addition to supporting the creation of a highly skilled workforce, the project will strengthen Qu\u00e9bec\u2019s innovation ecosystem by establishing unique integrated platforms for RNA synthesis and purification, attracting international partners, and positioning the province as a leader in RNA based medicines\u2014with significant economic, scientific, and health benefits.<\/p>\n","protected":false},"featured_media":3832,"template":"","project-category":[94],"class_list":["post-7920","project","type-project","status-publish","has-post-thumbnail","hentry","project-category-platforms-and-databases"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project\/7920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/project"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/3832"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=7920"}],"wp:term":[{"taxonomy":"project-category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project-category?post=7920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}